Date: 2011-03-15
Type of information: Licensing agreement
Compound: Acuform® Technology and Glumetza® Data
Company: Depomed (USA) Boehringer Ingelheim (Germany)
Therapeutic area: Metabolic diseases
Type agreement: licensing
Action mechanism:
Disease: type 2 diabetes
Details: Boehringer Ingelheim has licensed worldwide rights to Depomed's Acuform® gastric retentive drug delivery technology to develop and commercialize certain fixed dose combination product(s) which include extended release metformin and proprietary Boehringer Ingelheim compound(s) in development for type 2 diabetes. Boehringer Ingelheim has also been granted a right of reference to the Glumetza® (extended release metformin hydrochloride tablets) NDA and associated data for use in potential regulatory submission processes. Under the terms of the agreement, Boehringer Ingelheim is responsible for development and commercialization of the product(s).
Financial terms: Depomed will receive a $12.5 million license fee, $10 million of which is payable upfront, with an additional $2.5 million payable upon delivery of experimental batches of prototype formulations. Depomed is also eligible to receive additional milestone payments based on regulatory filing and approval events, and royalties on worldwide net sales of product(s). Further details of the agreement were not disclosed.
Latest news:
